[HTML][HTML] Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current
M Gritti, R Würth, M Angelini, F Barbieri, M Peretti… - Oncotarget, 2014 - ncbi.nlm.nih.gov
M Gritti, R Würth, M Angelini, F Barbieri, M Peretti, E Pizzi, A Pattarozzi, E Carra, R Sirito…
Oncotarget, 2014•ncbi.nlm.nih.govMetformin repositioning as antitumoral agent: selective antiproliferative effects in human
glioblastoma stem cells, via inhibition of CLIC1-mediated ion current - PMC Back to Top Skip to
main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content
Main Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User Guide
Journal List Oncotarget v.5(22); 2014 Nov PMC4294381 Other Formats PDF (4.7M) Actions
Cite Collections Share Permalink Copy RESOURCES Similar articles Cited by other articles …
glioblastoma stem cells, via inhibition of CLIC1-mediated ion current - PMC Back to Top Skip to
main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content
Main Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User Guide
Journal List Oncotarget v.5(22); 2014 Nov PMC4294381 Other Formats PDF (4.7M) Actions
Cite Collections Share Permalink Copy RESOURCES Similar articles Cited by other articles …
Abstract
Epidemiological and preclinical studies propose that metformin, a first-line drug for type-2 diabetes, exerts direct antitumor activity. Although several clinical trials are ongoing, the molecular mechanisms of this effect are unknown.
ncbi.nlm.nih.gov